Wednesday, July 8, 2026

pharma · Idiopathic Hypersomnia · Prader-Willi Syndrome · HRMY

Harmony Biosciences Holdings

Harmony Biosciences Holdings clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US HQ
2017 Founded
332 Employees
Public company Type
HRMY · NYSE Ticker
Company details
Status
Public
HQ
630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US
Founded
2017
Employees
332
Programs
21
Drugs
14
Patents
6
Intelligence · Clinical Programs

Harmony Biosciences Holdings projects

3 ClinicalTrials.gov programs sponsored by Harmony Biosciences Holdings.

Harmony Biosciences Holdings has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. HBS-201

    Harmony Biosciences Holdings

    Narcolepsy

    phase 1 small molecule completed

    1 trial
  2. MV-LASV

    Harmony Biosciences Holdings

    Lassa Virus Infection

    phase 1 mab completed

    1 trial
  3. Part 1

    Harmony Biosciences Holdings

    Drug Interaction

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Harmony Biosciences Holdings have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.